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An improved and reliable ultra-performance liquid chromatography/tandem mass spectrometry (UPLC–
MS/MS) method has been developed and validated for the determination of lercanidipine in human
plasma. Plasma samples with lercanidipine-d3 as an internal standard (IS) were prepared by solid phase
extraction on Phenomenex Strata-X cartridges using 100 mL of human plasma. Chromatographic analysis
was performed on UPLC BEH C18 (50 mm2.1 mm, 1.7 mm) column under isocratic conditions. Linear
calibration curves were obtained over a wide dynamic concentration range of 0.010–20.0 ng/mL. Matrix
effect was assessed by post-column infusion, post-extraction spiking and standard-line slope methods.
The mean extraction recovery was 494% for the analyte and IS. Inter-batch and intra-batch precision (%
CV) across ﬁve quality controls was o5.8%. Bioequivalence study was performed with 36 healthy sub-
jects after oral administration of 10 mg of lercanidipine and the assay reproducibility was evaluated by
reanalysis of 133 incurred samples.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hypertension, one of the major causes of cardiovascular dis-
eases, has affected young and elderly population in the world.
Antihypertensive drugs have been proven agents to prevent car-
diovascular morbidity and mortality since long ago [1,2]. Dihy-
dropyridine calcium channel blockers are a potent class of anti-
hypertensive drugs and work primarily as vasodilators. They are
widely used for the treatment and management of hypertension
and coronary artery diseases. Lercanidipine (LER), a third-genera-
tion dihydropyridine calcium channel blocker, helps in peripheral
vasodilation by preventing the entrance of calcium ions through
L-type calcium channels in cell membrane [3], and has shown high
efﬁcacy for patients with high cardiovascular risk and diffuse
atherosclerosis. LER has high lipophilicity, which is responsible for
smooth onset and prolonged therapeutic action compared with
the ﬁrst- and the second-generation calcium channel blockers. It
has shown lower incidence of adverse events such as lack of ac-
tivation of heart rate [4–6]. LER has a plasma half life of 8–10 h
which, however, does not relate to its duration of antihypertensiveon and hosting by Elsevier B.V. Th
University.
S. Shrivastav).activity. After oral administration, LER is almost completely ab-
sorbed from the gastrointestinal tract and reaches peak plasma
concentration within 1–3 h. It is approximately 98% protein bound
and has a distribution volume of 2–2.5 L/kg. LER gets extensively
metabolized by cytochrome P450 3A4 to inactive pyridine deri-
vatives which are eliminated in urine and feces [4,6].
To optimize drug therapy, reduce drug accumulation, and lessen
the frequency of adverse effects, it is essential to develop reliable,
rapid and sensitive bioanalytical methods. There are several methods
described in the literature for the determination of LER as a single
analyte [7–13] or in combination with other antihypertensive drugs
[14–17] in biological matrices. Enantioselective determination of LER
in human plasma has been described for pharmacokinetic studies
using chiral columns [7,8]. Racemic LER has been estimated using
different analytical techniques like voltammetry [9,10], high perfor-
mance liquid chromatography–ultraviolet detection (HPLC–UV) [11],
liquid chromatography–tandem mass spectrometry (LC–MS/MS) [12]
and ultra-performance liquid chromatography–tandem mass spec-
trometry (UPLC–MS/MS) [13] in human serum [9,10], human urine
[10], rabbit serum [11] and human plasma [12,13]. Salem et al. [12]
presented a selective and rapid method to determine LER in the
concentration range of 0.1–16 ng/mL within 10 min.
UPLC is a rapid separation technique with enhanced chromato-
graphic efﬁciency compared with conventional HPLC. Unlike HPLC,is is an open access article under the CC BY-NC-ND license
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and speed of analysis by optimized instrumentation operated with
1.7 mm particle size [18]. To the best of our knowledge, there is only
one UPLC–MS/MS method for the determination of LER with a limit
of quantitation of 0.05 ng/mL employing 1.0 mL of human plasma by
liquid–liquid extraction [13]. The present work aimed to improve
upon this method for routine sample analysis in a clinical laboratory.
The current validated method has superior sensitivity and employs
small plasma volume for processing compared with the existing
UPLC–MS/MS method [13]. Additionally, its reproducibility proven
through incurred sample reanalysis is free from matrix interference
and highly rugged.2. Experimental
2.1. Chemicals and materials
Reference standards of lercanidipine hydrochloride (LER, purity
99.66%) and lercanidipine-d3 hydrochloride (IS, purity 99.53%)
were obtained from Clearsynth Labs (P) Ltd. (Mumbai, India). HPLC
grade methanol and acetonitrile were obtained from Mallinckrodt
baker, S.A.de C.V. (Estado de Mexico, Mexico). Bio-ultra grade
ammonium formate and LC–MS grade formic acid were procured
from Sigma-Aldrich (St. louis, MO, USA). Solid phase extraction
(SPE) cartridges Phenomenex Strata™-X (30 mg, 1 mL) were pur-
chased from Phenomenex India (Hyderabad, India). Deionized
water used during the entire analysis was prepared using A Milli-Q
water puriﬁcation system from Millipore (Bangalore, India). Blank
human plasma was obtained from Supratech Micropath (Ahme-
dabad, India) and stored at 20 °C until use.
2.2. Liquid chromatographic and mass spectrometric conditions
Waters Acquity UPLC system from Waters Corporation (MA,
USA), together with Acquity UPLC BEH C18 (50 mm2.1 mm,
1.7 mm) analytical column that was maintained at 35 °C in a
column oven, was used for the analysis of LER and IS. The mobile
phase consisted of 2.0 mM ammonium formate in water (pH 2.5,
adjusted with formic acid) and acetonitrile (10:90, v/v) and
delivered at a ﬂow rate of 0.250 mL/min. The sample manager
temperature was maintained at 4 °C and the system pressure was
7200 psi. Waters Quattro Premier XE from Waters Corporation
(MA, USA) triple quadrupole mass spectrometer equipped with
electrospray ionization was used for ionization and detection of
LER and IS in the positive ionization mode. Optimized mass
parameters for LER and IS were set as follows: cone gas ﬂow, 85 L/
h; desolvation gas ﬂow, 740 L/h; capillary voltage, 2.2 kV; source
temperature, 120 °C; desolvation temperature, 320 °C; and ex-
tractor volts, 5.00 V. The pressure of argon gas used for collision
activation dissociation was 0.110 Pa. Quantitation was performed
by monitoring transitions of m/z 612.2-280.1 for LER and m/z
615.2-283.1 for IS using multiple reaction monitoring (MRM)
mode. Compound dependent parameters like cone voltage and
collision energy were set at 70 V and 30 eV for LER and IS, re-
spectively. Quadrupoles 1 and 3 were sustained at unit mass re-
solution and the dwell time was set at 100 ms. MassLynx software
version 4.1 was used to control all UPLC and MS parameters.
2.3. Standard stock and spiked plasma samples
The standard stock solution of LER (100 mg/mL) was prepared
by dissolving its accurately weighed amount in methanol, and
intermediate stock solutions (10.0 and 0.50 mg/mL) were prepared
in methanol:water (50:50, v/v). Calibration stansdards (CSs) and
quality control (QC) samples were prepared by spiking blankplasma with corresponding stock solution. CSs were made at
0.010, 0.020, 0.060, 0.200, 0.400, 0.800, 2.00, 4.00, 10.0, 20.0 ng/mL
concentrations, while QC samples were prepared at 16.0 ng/mL
(high quality control, HQC), 8.00 ng/mL/2.40 ng/mL (medium
quality control, MQC-1/2), 0.030 ng/mL (low quality control, LQC)
and 0.010 ng/mL (lower limit of quantiﬁcation quality control,
LLOQ QC). Stock solution (100 mg/mL) of IS was prepared by dis-
solving 1.0 mg of lercanidipine-d3 in 10.0 mL of methanol and
further diluted to prepare its working solution (40.0 ng/mL) in
methanol: water (50:50, v/v). Standard stock and working solu-
tions used for spiking were stored at 5 °C, while CSs and QC
samples in plasma were kept at 70 °C until use.
2.4. Sample preparation
In order to avoid photodegradation of LER, the entire extraction
process was performed under yellow light (570–580 nm). Prior to
extraction, all frozen subject samples, CSs and QC samples were
thawed and allowed to equilibrate at room temperature. 20 mL of
internal standard was added to an aliquot of 100 mL of spiked
plasma sample and vortexed for 10 s. Further, 100 mL of 2.0 mM
ammonium formate in water (pH 2.5, adjusted with formic acid)
was added and vortexed for another 10 s and then centrifuged
at 13,148g for 5 min at 10 °C. The samples were loaded on
Phenomenex StrataTM-X (30 mg, 1 mL) cartridges, previously
conditioned with 1 mL methanol followed by 1 mL of 2.0 mM
ammonium formate in water (pH 2.5). The samples were washed
with 21 mL of 5% methanol in water and the cartridges were
dried over nitrogen (1.72105 Pa) at a ﬂow rate of 2.4 L/min for
1 min. Elution of LER and IS was carried out with 0.5 mL of
methanol. Then, the organic phase was evaporated to dryness
under a gentle stream of nitrogen gas and the residue was
reconstituted with 100 mL of mobile phase and brieﬂy vortexed for
15 s. 10 mL was injected into the chromatographic system.
2.5. Method validation
The detailed UPLC–MS/MS method validation was based on
standard guidelines [19] and similar to our previous work [20].
System suitability experiment was performed by injecting six
consecutive injections using aqueous standard mixture of LER
(8.0 ng/mL) and IS at the start of each batch during method vali-
dation. System performance was studied by injecting one ex-
tracted blank plasma (without analyte and IS) and one extracted
LLOQ sample with IS at the beginning of each analytical batch and
before re-injecting any sample during method validation. The
carryover effect of the autosampler was evaluated by sequentially
injecting extracted blank plasma, upper limit of quantitation
(ULOQ) sample, extracted blank plasma, LLOQ sample, extracted
blank plasma at the start and end of each batch.
Method selectivity was assessed for potential matrix inter-
ferences in ten batches (6 normal lots of Na-heparin plasma,
2 haemolysed plasma lots, and 2 lipemic plasma lots) of blank
human plasma by extraction and inspection of the resulting
chromatograms for interfering peaks. The selectivity of the
method towards commonly used medications by human volun-
teers, involving paracetamol, chlorpheniramine maleate, diclofe-
nac, caffeine, acetylsalicylic acid and ibuprofen, was also ascer-
tained. Their stock solutions (100 mg/mL) were prepared by dis-
solving requisite amount in methanol. Further, working solutions
(1.0 mg/mL) were prepared in the mobile phase and 10 mL was in-
jected to check for any possible interference at the retention time
of the analyte and IS.
Five calibration lines containing ten non-zero concentrations
were used to determine linearity. A quadratic, 1/x2, least-squares
regression algorithm was used to plot the peak area ratio (analyte/
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equations were then used to calculate the predicted concentra-
tions in all samples within analytical runs. The correlation coefﬁ-
cient for each calibration curve must be Z0.99 for LER. The lowest
concentration standard on the calibration line was accepted as the
LLOQ, if the analyte response was at least ten times more than that
of extracted blank plasma. Reinjection reproducibility for extracted
samples was also checked by reinjection of one entire analytical
run after storage at 5 °C.
Intra-day accuracy and precision were evaluated by replicate
analysis of plasma samples on the same day. The analytical run
consisted of a calibration curve and six replicates of LLOQ, LQC,
MQC-1/2 and HQC samples. The inter-day accuracy and precision
were assessed by analyzing ﬁve precision and accuracy batches on
three consecutive validation days. The precision (% CV) at each
concentration level from the nominal concentration should not be
greater than 15%. Similarly, the mean accuracy should be within
85%–115%, except for the LLOQ where it can be within 80%–120% of
the nominal concentration.
Ion suppression/enhancement effects on the method sensitivity
were evaluated by post column analyte infusion experiment.
Brieﬂy, a standard solution containing LER (at ULOQ level) was
infused post-column into the mobile phase at 5 mL/min employing
infusion pump. Aliquots of 10 mL of extracted control blank plasma
sample were then injected into the column by the autosampler
and chromatograms were acquired for the analyte and IS.
Extraction recovery of LER and IS from human plasma was
evaluated in six replicates by comparing the mean peak area re-
sponses of pre-extraction fortiﬁed samples with those of post-
extraction fortiﬁed samples. Absolute matrix effect was assessed
by comparing the mean area response of post-extraction fortiﬁed
samples with mean area of solutions prepared in mobile phase
solutions (neat standards) at HQC, MQC-1/2 and LQC levels [21].
IS-normalized matrix factors (MFs, analyte/IS) were calculated to
assess the variability of the results due to matrix effects. Relative
matrix effect was assessed from the precision (% CV) values of the
slopes of the calibration curves prepared from eight different
plasma lots/sources, which included one haemolysed plasma and
one lipemic plasma. To prove the absence of matrix effect, % CV
should be less than 3%–4% for method applicability to support
clinical studies [22].
Stability tests were conducted in stock solutions of LER and IS
for short-term and long-term stability at 25 °C and 5 °C, respec-
tively. The acceptance criterion was 710.0% deviation from the
nominal value. All stability results for spiked plasma samples were
evaluated by measuring the area ratio response (LER/IS) of stability
samples against freshly prepared comparison standards at LQC
and HQC levels. Bench top, processed sample at room temperature
and in cooling chamber at 5 °C, autosampler stability, freeze-thaw
(20 °C and 70 °C) and long-term (20 °C and 70 °C) stability
of the analyte in plasma were studied at LQC and HQC levels using
six replicates. The samples were considered stable if the deviation
from the mean calculated concentration of freshly prepared
quality control samples was within 715.0%.
Method ruggedness was veriﬁed using two precision and ac-
curacy batches. The ﬁrst batch was analyzed on two different
columns of the same make but different batch number, while the
second batch was analyzed by two different analysts who did not
participate in method validation. The ability to dilute samples
which could be above the upper limit of the calibration range was
validated by analyzing six replicate samples containing 40 ng/mL
of LER in the screened plasma after ﬁve-/ten-fold dilution re-
spectively. The precision and accuracy of dilution reliability was
determined by comparing the samples against freshly prepared
calibration curve standards.2.6. Bioequivalence study and incurred sample reanalysis
The study was an open-label, randomized, balanced, crossover,
two-treatment, two-period and two-sequence design to de-
termine the bioavailability, intra-subject variability and bioequi-
valence between a single dose of 10 mg of LERCANs (Aspen
Pharmacare, South Africa) and 10 mg of ZANIDIPs (Medley S.A.
Industria Farmaceutica, Brazil) LER tablet formulations in 36 adult
(aged 18–45 years) healthy volunteers under fed conditions. Each
subject was checked to be healthy through medical history, phy-
sical examination and routine laboratory tests. All the subjects
were informed about the objectives and possible risks of the study
and were given a written consent. The study protocol was ap-
proved by an independent ethics committee constituted as per
Indian Council of Medical Research (ICMR) and was performed in
accordance with International Conference on Harmonization, E6
Good Clinical Practice guidelines [23]. The subjects were orally
administered a single dose of the formulations after recommended
wash out period of 7 days with 240 mL of water. Further, under fed
conditions, the subjects were given high-fat and high-calorie
breakfast (consisting of 250 mL milk with 5 g sugar, 35 g walnuts,
two slices of bread with cheese and two cheese cutlets, containing
969 cal in total) 30 min before giving the drug under investigation.
After administration, blood samples were collected at 0.00 (pre-
dose), 0.50, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00,
4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 20.00, 24.00 and
48.00 h for test and reference formulations. Plasma was separated
by centrifugation and kept frozen at 70 °C until analysis. During
entire analysis, subjects had a standard diet while water intake
was unmonitored. Non-compartmental model using WinNonlin
software version 5.2.1 (Pharsight Corporation, Sunnyvale, CA, USA)
was used to evaluate pharmacokinetic parameters of LER. To de-
termine whether the formulations were pharmacokinetically
equivalent, Cmax, AUC0–48 and AUC0–inf, and their ratios (test/re-
ference) using log transformed data were assessed. The drug for-
mulations were considered pharmacokinetically equivalent if the
difference between the compared parameters was statistically
nonsigniﬁcant (PZ0.05) and the 90% conﬁdence intervals (CI) for
these parameters were within 80%–125%. An incurred sample re-
analysis (ISR) was also done by selecting 133 samples which were
near the Cmax and the elimination phase in the pharmacokinetic
proﬁle of the drug. The results obtained were compared with the
data obtained previously for the same sample following the same
procedure. The percent change value between the two measure-
ments should be within 720% as reported previously [24].3. Results and discussion
3.1. UPLC–MS/MS method optimization
Method development was initiated to improve upon a pre-
viously published UPLC–MS/MS method for higher sensitivity,
lower plasma volume for processing, minimized consumption of
toxic organic solvent and reduction in overall analysis time [13].
Thus, the extraction procedure, mass spectrometry parameters,
and chromatographic conditions were suitably optimized.
3.1.1. Mass spectrometry
Measurement of LER and IS levels in human plasma was per-
formed using electrospray ionization (ESI) in the positive ioniza-
tion mode for UPLC–MS/MS analyses to attain high sensitivity and
a good linearity in regression curves. The full scan Q1 mass spectra
in the positive mode gave predominantly protonated precursor
ions at m/z 612.2 and 615.2 for LER and IS, respectively. Frag-
mentation of protonated precursor ions gave highly intensive and
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spectively. The source dependent and compound dependent
parameters were suitably optimized to obtain a consistent and
sufﬁcient response for the analyte. Thus, MRM transitions of m/z
612.2/280.1 for LER and m/z 615.2/283.1 for IS were ﬁnalized for
quantitation. A dwell time of 100 ms was adequate and there was
no cross talk between MRMs of LER and IS.
3.1.2. Liquid chromatography
Chromatographic analysis was initiated to obtain adequate re-
tention, sharp peak shape and short run time for LER and IS, with
minimum matrix interference and solvent consumption. Selection
of proper mobile phase and its pH was also investigated in the
present work. Different combinations of acetonitrile/methanol and
acidic modiﬁers (formic acid, glacial acetic acid, ammonium for-
mate) were tested for adequate response and peak shape on Wa-
ters Acquity UPLC BEH C18 (50 mm2.1 mm, 1.7 mm) column. It
was observed that higher acetonitrile content enabled shorter run
time and better peak shape, while the acidic additive helped to
obtain adequate response for the analyte and IS. Nevertheless, theFig. 1. Representative MRM ion-chromatograms of (A) blank plasma with working solut
at LLOQ and IS, and (C) lercanidipine in real subject sample at Cmax and IS after adminibest chromatographic conditions were obtained using 2.0 mM
ammonium formate in water, pH 2.5 adjusted with formic acid-
acetonitrile (10:90, v/v) as the mobile phase under isocratic con-
ditions. It ensured sufﬁcient retention and elution of the analyte
and IS within 1.0 min. The retention time for LER and IS was 0.71
and 0.72 min, respectively. Representative UPLC–MS/MS chroma-
tograms of blank plasma fortiﬁed with IS, LER at LLOQ and an
actual subject sample at Cmax illustrate the selectivity of the pro-
posed method (Fig. 1). Use of deuterated IS, lercanidipine-d3,
helped to compensate any possible variability during extraction
and LC–MS/MS analysis. Additionally, there were no interfering
signals at the retention time of LER or IS due to commonly used
medications by human volunteers. Post-column infusion chro-
matogram showed no ion suppression or enhancement at the re-
tention time of LER and IS (Fig. 2).
3.1.3. Plasma extraction
Due to high lipophilicity of LER, liquid–liquid extraction (LLE)
has been used extensively for quantitative extraction of LER from
human plasma [7,12–15]. However, in our effort to minimize usageion of lercanidipine-d3 (m/z 615.2-283.1) (IS), (B) lercanidipine (m/z 612.2-280.1)
stration of 10 mg dose of lercanidipine hydrochloride, LERCANs.
Fig. 2. Injection of extracted blank human plasma during post-column infusion of (A) lercanidipine at ULOQ level and (B) lercanidipine-d3.
Table 1
Precision and accuracy data for lercanidipine.
QC level Intra-batch (n¼6; single
batch)
Inter-batch (n¼30; 6 from
each batch)
Mean
conc.
found
(ng/mL)
CV (%) Accuracy (%) Mean
conc.
found
(ng/mL)
CV (%) Accuracy (%)
HQC 15.7 2.49 98.1 16.2 1.48 101.2
MQC-1 8.13 2.04 101.6 7.90 1.89 98.7
MQC-2 2.37 2.17 98.7 2.36 3.52 98.3
LQC 0.0302 4.58 100.6 0.0309 5.72 103.0
LLOQ QC 0.0102 5.41 102.0 0.0101 5.33 101.0
Table 2
Extraction recovery for lercanidipine and lercanidipine-d3 (n¼6).
QC level Lercanidipine Lercanidipine-d3
Area response Extraction
recovery (%)
(B/A)
Area response Extraction
recovery (%)
(B/A)A B A B
HQC 452,157 445,829 98.6 227,342 221,658 97.5
MQC-1 225,687 215,305 95.4 231,376 217,725 94.1
MQC-2 67,548 65,589 97.1 229,476 219,379 95.6
LQC 845 797 94.3 221,683 214,367 96.7
A: mean area response of six replicates prepared by spiking in extracted blank
plasma;
B: mean area response of six replicates prepared by spiking before extraction.
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with Phenomenex StrataTM-X cartridges was employed. Two pre-
vious methodologies have employed SPE on Oasis HLB [17] and
mixed mode C8/cation exchange cartridges [14] with satisfactory
recovery for LER from human plasma. To improve the extraction
recovery, 2.0 mM ammonium formate in water (pH 2.5, adjusted
with formic acid) was added to plasma sample before loading for
conditioning of cartridges. The mean extraction recovery obtained
was highly consistent as well as quantitative across four QC levels.
3.2. Assay performance and validation results
The precision (% CV) for system suitability test was observed in
the range of 0.08%–0.15% for the retention time and 0.75%–1.34%
for the area response of LER and IS. The observed signal-to-noise
ratio for system performance was Z24 for both LER and IS. The
column and autosampler carryover evaluation showed negligible
carry-over in blank plasma (r0.13% of LLOQ sample) after the
injection of ULOQ sample. The method selectivity was assessed in
ten different batches of blank plasma to check for the interference
of endogenous matrix components in the quantitation of LER.
There was no major interference at the retention time of the
analyte in any of the batches.
LER showed good linearity (r2Z0.9996) through the studied
concentration range of 0.010–20 ng/mL. The accuracy and preci-
sion values for the calibration curve standards ranged from 98.3%
to 101.3% and 0.65% to 2.60%, respectively. The limit of detection
(LOD) and LLOQ of the method for LER was 0.003 and 0.010 ng/mL
at a signal-to-noise ratio of 24 and 10, respectively. The reinjection
reproducibility expressed as % CV in the measurement of retention
time for LER was r0.74 for 100 injections on the same column.
The intra and inter-batch precision and accuracy results for LER
across ﬁve QC levels are presented in Table 1. The intra-batch
precision (% CV) and accuracy ranged from 2.04%–5.41% and
98.1%–102.0%, respectively. Similar to inter-batch study, the pre-
cision varied from 1.48% to 5.72% and the accuracy was within
98.3%–103.0%.
The extraction recoveries for LER and IS are presented in Ta-
ble 2. The mean extraction recovery for LER and IS varied from
94.3% to 98.6% and 94.1% to 97.5% across QC levels. Evaluation of
MFs is essential as the presence of unmonitored co-eluting com-
pounds from the matrix can affect the accuracy, precision, rug-
gedness and overall reliability of a validated method. MFs were
checked in lipemic and haemolysed plasma samples in addition to
normal heparinised plasma. MFs can be determined from the peak
area response for the analyte and IS respectively, while the ratio of
the two factors yields IS-normalized MF for the analyte. Further,
the IS-normalized MFs using stable-isotope labeled IS should be
close to unity because of the similarities in the chemical properties
and elution behavior of the analyte and IS. The IS-normalized MFsranged from 0.98 to 1.04 (Table 3). Additionally, the coefﬁcient of
variation (% CV) of the slopes of calibration lines for relative matrix
effect in eight different plasma lots was 2.94% as shown in Sup-
plementary Table 1.
Stability of LER in plasma under various conditions at two QC
levels with the values for percent change is shown in Table 4.
Samples for short-term and long-term stock solution stability re-
mained unchanged up to 24 h and 48 days, respectively, for LER
and IS. Bench top stability of LER in plasma was established up to
16 h and was stable for minimum of ﬁve freeze-thaw cycles at
20 °C and 70 °C. Autosampler stability of the spiked quality
control samples maintained at 4 °C was determined up to 78 h
without signiﬁcant drug loss. For long-term stability, the spiked
plasma samples stored at 20 °C and 70 °C were found stable
for a minimum period of 164 days.
For method ruggedness, the precision (% CV) and accuracy va-
lues for different columns ranged from 1.4% to 3.2% and 96.8% to
Table 3
Matrix factors for lercanidipine and lercanidipine-d3 (n¼6).
QC level Lercanidipine Lercanidipine-d3
Area response Matrix factor
(A/B)
Area response Matrix factor
(A/B)
A B A B
HQC 452,157 438,987 1.03 227,342 231,982 0.98
MQC-1 225,687 221,262 1.02 231,376 222,476 1.04
MQC-2 67,548 67,468 1.00 229,476 231,794 0.99
LQC 845 820 1.03 221,683 219,488 1.01
A: Mean area response of six replicates prepared by spiking in extracted blank
plasma;
B: Mean area response of six replicates prepared by spiking in mobile phase (neat
samples).
Table 4
Stability of lercanidipine in plasma under various conditions (n¼6).
Storage conditions QC level Nominal
conc.
(ng/mL)
Mean stability
sample7SD
(ng/mL)
Change (%)
Bench top stability at
room temperature,
16 h
HQC 16.0 15.5670.24 3.13
LQC 0.030 0.030470.0003 1.33
Freeze-thaw stability
after 5th cycle at
20 °C
HQC 16.0 15.8470.35 1.25
LQC 0.030 0.030370.0007 1.00
Freeze-thaw stability
after 5th cycle at
70 °C
HQC 16.0 16.3170.31 1.88
LQC 0.030 0.029670.0006 1.33
Processed sample
stability at room
temperature, 14 h
HQC 16.0 16.2070.33 1.25
LQC 0.030 0.030170.0006 0.33
Autosampler stabi-
lity at 4 °C, 78 h
HQC 16.0 16.4270.57 2.50
LQC 0.030 0.029770.0005 1.00
Processed sample
stability (wet ex-
tract), at 2–8 °C ,
73 h
HQC 16.0 15.9070.29 0.63
LQC 0.030 0.029970.0007 0.33
Long-term stability
at 20 °C, 164
days
HQC 16.0 15.6770.53 2.50
LQC 0.030 0.030270.0004 0.67
Long-term stability
at 70 °C, 164
days
HQC 16.0 15.7970.41 1.88
LQC 0.030 0.030470.0007 1.33
Change % 100%Mean stability samples Mean comparison samples
Mean comparison samples
( ) = ×– .
Fig. 3. Mean plasma concentration-time proﬁle of lercanidipine after oral admin-
istration of 10 mg of LERCANs and 10 mg of ZANIDIPs tablet formulations by 36
healthy Indian volunteers.
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and accuracy results for different analysts were within 1.8%–2.9%
and 97.6%–104.5%, respectively. The precision (% CV) for dilution
reliability of 1/5th and 1/10th dilution was between 1.66% and
2.63%, while the accuracy results were within 97.1%–103.7%.
3.3. Application to a bioequivalence study and incurred sample
reanalysis
The UPLC–MS/MS method was successfully applied to de-
termine LER concentration in human plasma samples after oral
administration of a single 10 mg dose of LERCANs and ZANIDIPs
formulations. The present study was conducted under fed condi-
tions as it has been shown that food increases the bioavailability of
LER hydrochloride by three folds [25]. Fig. 3 presents the mean
plasma concentration vs. time proﬁle of LER in 36 healthy subjects.
The mean pharmacokinetic parameters obtained for both the
formulations are compiled in Table 5. The Cmax, t1/2, AUC0–t, and
AUC0–inf values were comparable with a similar study with 10 mg
of LER hydrochloride [25]; however, the Tmax values wereapproximately half of those obtained in the present work. This
could be related to genetic difference, type of food, gender, age,
weight, and other renal and hepatic functions. Nevertheless, there
was no obvious statistical difference between the two formula-
tions in any parameter. The ratios of mean log-transformed Cmax,
AUC0–48, and AUC0–inf and their 90% CIs were all within the deﬁned
bioequivalence range of 80%–125% (Table 5). These observations
validate the bioequivalence of the two products in terms of rate
and extent of absorption. Moreover, there was no adverse event
during the study. About 2700 samples, which included CSs, QCs
and subject samples, were analyzed in a period of 9 days and the
precision and accuracy were well within the acceptable limits.
Further, the reproducibility test performed with 133 incurred
samples showed the percent change within 710% of the initial
analysis results, which conﬁrms the reproducibility of the pro-
posed method.
3.4. Comparison with reported methods
The current method is more sensitive and employs less plasma
volume for processing compared with all other procedures for
determination of LER in human plasma. Further, the consumption
of organic diluent for extraction and chromatography is sig-
niﬁcantly less than that of available methods. The on-column
loading of LER at ULOQ was only 0.20 ng per sample injection.
Methods reported for the analysis of LER by LC–MS/MS are based
on its enantioselective determination in human plasma [7], si-
multaneous determination with other antihypertensive drugs for
toxicokinetic studies [17], rapid screening for forensic and clinical
studies [14] and for pharmacokinetic study with healthy subjects
[12] or patients [13]. The present method with a linear range of
0.01–20 ng/mL adequately covers the therapeutic plasma con-
centration range of 1.2–13.6 ng/mL for LER. The LLOQ of
0.01 ng/mL was established to have a better assessment of LER
pharmacokinetics, especially during the elimination phase. To the
best of our knowledge, this is the ﬁrst report on bioequivalence
study in healthy Indian subjects. Additionally, the ISR results have
proved the reproducibility of method which has not been reported
in any previous study on LER. A detailed summary of all liquid
chromatography–tandem mass spectrometry methods developed
for LER in human plasma is presented in Table 6 to highlight the
merits of the present method.4. Conclusion
A selective, sensitive and rugged UPLC–MS/MS method for the
quantitation of LER in human plasma has been developed and fully
Table 6
Comparison of salient features of the present method with reported LC–MS/MS methods for lercanidipine in human plasma.
Sr.
no.
LLOQ
(ng/mL)
Linear
range
(ng/mL)
Sample
processing
volume
(mL)
Extraction technique Maximum on-col-
umn analyte load-
ing per injection
(ng)
Organic solvent
consumption per
sample analysis
(mL)
Post-column infusion study; matrix
effect; application
Ref.
1a 0.025 0.025–
50.0
1000 LLE with hexane-isopropanol 20.0 17.5 Yes; –; Stereoselective analysis of
10 mg of lercanidipine tablet, Zanidip
in one healthy volunteer
[7]
2 0.10 0.10–
16.0
1000 LLE with hexane-ethyl acetate 9.6 27.2 –; Yes; Bioequivalence study with 20
mg of lercanidipine tablet in 36 heal-
thy volunteers
[12]
3b 0.05 0.050–
30.0
500 LLE with methyl tert-butyl ether 3.0 4.2 –; Yes; Bioavailability study with
10 mg of lercanidipine tablet, Zanidip
in 3 patients
[13]
4c 1.00 – 1000 Automated SPE on mixed-mode C8/cation
exchange cartridges
2.72 9.0 –; –; Screening of 11 dihydropyridine
calcium channel blockers in plasma for
forensic and clinical studies
[14]
5d 1.00 1.0–
2000
200 SPE on Oasis HLB C18 cartridiges 8.0 22.0 –; Yes; Toxicokinetic study in 24
healthy beagle dogs
[17]
6 b 0.010 0.010–
20.0
100 SPE on Phenomenex Strata-X cartridges 0.20 1.9 Yes; Yes; Bioequivalence study with
10 mg of lercanidipine tablets, Zanidip
and Lercan in 36 healthy volunteers;
Yes
PW
LLOQ: lower limit of quantitation; LLE: liquid–liquid extraction; SPE: solid phase extraction; PW: present work.
a Enantiomeric determination.
b UPLC–MS/MS method.
c Together with 10 dihydropyridine calcium channel blockers.
d Along with benazepril and benazeprilat.
Table 5
Mean pharmacokinetic parameters (7SD) and comparison of treatment ratios and 90% CIs of natural log (Ln)-transformed parameters following oral administration of
10 mg of lercanidipine tablet formulation by 36 healthy Indian subjects under fed condition.
Parameter Mean LERCAN/ZANIDIP (%) 90% CI (Lower–upper) Power Intra-subject variation (% CV)
LERCAN ZANIDIP
Cmax (ng/mL) 9.16±1.46 9.39±1.84 97.55 94.04–101.13 0.9996 6.05
AUC0–48 (h ng/mL) 17.8±4.05 19.0±4.51 94.05 91.23–96.82 0.9993 5.01
AUC0–inf (h ng/mL) 21.1±5.82 22.8±6.06 92.61 88.41–96.60 0.9998 7.43
Tmax (h) 1.67±0.28 1.73±0.26 – – – –
t1/2 (h) 3.36±0.96 3.54±0.64 – – – –
Kel (1/h) 0.12±0.02 0.13±0.01 – – – –
D.V. Chaudhary et al. / Journal of Pharmaceutical Analysis 6 (2016) 87–94 93validated as per USFDA guidelines. The method presents perceived
advantage over the existing UPLC–MS/MS method in terms of
lower sample requirement for processing and ﬁve-fold higher
sensitivity. Although the chromatographic analysis time is iden-
tical to the existing UPLC–MS/MS method, the consumption of
organic solvent (for chromatography and extraction) in the present
work is considerably lower. Moreover, matrix effect is extensively
evaluated through post-column infusion, post-extraction spiking
and calibration line slope methods. Additionally, incurred sample
reanalysis study was also performed to prove the method re-
producibility which has not been reported in existing procedures
for LER. Finally, the present method shows adequate sensitivity
and selectivity for the quantiﬁcation of LER in human plasma in
clinical study with healthy volunteers.Acknowledgments
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